Pioglitazone in type 2 diabetics is associated with a 1.2 increased risk of bladder cancer. The absolute risk of bladder cancer in this study of type 2 diabetics was 0.9 per 1000 patient years. With at least 2 years of pioglitazone use, the risk increased to 1.2 per 1000 patient years. The number needed to harm was approximately 750 for a cumulative pioglitazone use of 28,000 mg and 1100 for a cumulative pioglitazone use duration of more than 24 months. Rosiglitazone does not appear to be associated with an increased risk of bladder cancer.
BMJ 2012;344:e3645 (retrieved Jun, 2012).
There are currently 1090 pearls in the database. While every attempt has been made to ensure accuracy, mistakes can and do occur. Use databank at your own risk.
All pearls © 2024 by the Internet Medical Association. Click Here to view more medical pearls.
|